Consensus Gilead Sciences, Inc.

Stocks

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 01:30:00 29/08/2026 am IST			5-day change	1st Jan Change
145.68 ^USD	-2.14%		-0.30%	+18.69%

28/08	Warsh Takes the Stage
28/08	A tale of two markets

Evolution of the Average Target: Gilead Sciences, Inc.

Evolution of the Target Price: Gilead Sciences, Inc.

Changes in Analyst Recommendations: Gilead Sciences, Inc.

734b0295f618ecea6d5b.Uwd7d-NcdBhG1N14anopLy1UOdbF3_IO1J0DLUqCz2c.ElgCBLEoB0oOmpU-EhtsHXcsc7qnkLNr469NQyfG_jgeTAtD0CoBTgiuvg~08c9243633df637b16bf82e1fcd68547

Analysts' recommendations: Gilead Sciences, Inc.

05/08	Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says	MT
05/08	Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126	MT
05/08	Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130	MT
05/08	RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating	MT
04/08	Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says	MT
28/07	Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating	MT
23/07	Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating	MT
21/07	Gilead Sciences Shares Fall After Downgrade From Leerink Partners	MT
21/07	Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike…
21/07	Leerink Partners Downgrades Gilead Sciences to Market Perform From Outperform, Adjusts PT to $127 From $146	MT
08/07	Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says	MT
08/07	Morgan Stanley Adjusts Price Target Gilead Sciences to $166 From $168, Maintains Overweight Rating	MT
07/07	Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157	MT
07/07	RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating	MT
06/07	Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow…
06/07	HSBC Upgrades Gilead Sciences to Buy From Hold, Adjusts Price Target to $155 From $133	MT
08/06	Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says	MT
20/05	Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target is $165	MT
19/05	Daiwa Securities Adjusts PT on Gilead Sciences to $150 From $161, Maintains Outperform Rating	MT
11/05	Gilead's Emvistegrast Readout Unlikely to Move Stock, RBC Says	MT
11/05	Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $167 From $170	MT
08/05	Leerink Partners Adjusts Price Target on Gilead Sciences to $146 From $148	MT
08/05	Gilead Sciences' Increased Yeztugo Guidance is 'Good Enough' for the Stock, Morgan Stanley Says	MT
08/05	Morgan Stanley Adjusts Price Target on Gilead Sciences to $168 From $175	MT
28/04	Morgan Stanley Adjusts Gilead Sciences Price Target to $175 From $171, Maintains Overweight Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	GILEAD SCIENCES, INC.					+8.05%
	ELI LILLY AND COMPANY					+11.96%
	JOHNSON & JOHNSON					+1.66%
	ABBVIE INC.					+8.26%
	ROCHE HOLDING AG					+3.24%
	NOVARTIS AG					+0.76%
	ASTRAZENECA PLC					+31.03%
	AMGEN INC.					-10.16%
	NOVO NORDISK A/S					+4.82%
	PFIZER INC.					+2.31%
	Average					+6.19%
	Weighted average by Cap.					+7.05%